<p>In recent years, the utilization of single-port robotic-assisted pyeloplasty (SP-RP) has been growing. However, it is still unclear whether it offers better outcomes relative to multi-port robotic-assisted pyeloplasty (MP-RP). To investigate this, a meta-analysis was executed comparing the perioperative and functional outcomes between SP-RP and MP-RP. We systematically searched SinoMed, Google Scholar, Embase, PubMed, and Scopus, up to June 1, 2025. All outcomes were pooled using a random-effects model, heterogeneity was assessed using both <i>I</i><sup>2</sup> and <i>τ</i><sup>2</sup>. Additionally, sensitivity analyses were executed to stabilize results with high heterogeneity. This meta-analysis included 229 patients from seven studies, who underwent either SP-RP or MP-RP. Regarding surgical success rates, patients undergoing SP-RP or MP-RP demonstrated comparable effectiveness (RR = 1.00, 95% CI 0.96 to 1.06, <i>P</i> = 0.87, <i>I</i><sup>2</sup> = 0%, <i>τ</i><sup>2</sup> = 0). Compared to patients receiving MP-RP, patients undergoing SP-RP showed similar results in surgery time (WMD = −2.81&#xa0;min, 95% CI −20.94 to 15.32&#xa0;min, <i>P</i> = 0.76, <i>I</i><sup>2</sup> = 72%, <i>τ</i><sup>2</sup> = 409.36), blood loss(WMD =  −3.97&#xa0;ml, 95% CI −9.25 to 1.30&#xa0;ml, <i>P</i> = 0.14, <i>I</i><sup>2</sup> = 32%, <i>τ</i><sup>2</sup> = 12.61), complication rates(RR = 0.90, 95% CI 0.42 to 1.92, <i>P</i> = 0.78, <i>I</i><sup>2</sup> = 0%, <i>τ</i><sup>2</sup> = 0), length of hospital stay (WMD = −0.42&#xa0;days, 95% CI −0.90 to 0.06&#xa0;days, <i>P</i> = 0.09, <i>I</i><sup>2</sup> = 74%, <i>τ</i><sup>2</sup> = 0.25), pain scores at discharge (WMD = 0.23, 95% CI −0.52 to 0.97, <i>P</i> = 0.55, <i>I</i><sup>2</sup> = 37%, <i>τ</i><sup>2</sup> = 0.17), and renal function recovery(WMD = 0.79&#xa0;mL/min/1.73&#xa0;m<sup>2</sup>, 95% CI −4.59 to 6.17&#xa0;mL/min/1.73&#xa0;m<sup>2</sup>, <i>P</i> = 0.77, <i>I</i><sup>2</sup> = 67%, <i>τ</i><sup>2</sup> = 10.88). Statistically, the differences between the two were not significant. However, during the sensitivity analysis, compared to MP-RP, we found that excluding Beksac’s study led to a significantly shorter hospital stay for SP-RP. This exclusion also reduced heterogeneity, resulting in more stable outcomes (WMD = −0.31&#xa0;days, 95% CI −0.56 to −0.06&#xa0;days, <i>P</i> = 0.01, <i>I</i><sup>2</sup> = 0%, <i>τ</i><sup>2</sup> = 0). SP-RP offers comparable effectiveness and safety to MP-RP, with consistently better cosmetic outcomes. A possible reduction in hospital stay was observed only in the sensitivity analysis and should be interpreted with caution.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Robot-assisted pyeloplasty in ureteropelvic junction obstruction (UPJO): a systematic comparison of single- and multiple-port techniques

  • Ying Liu,
  • Jing He,
  • Lei Wang,
  • Zhi Wen,
  • Yan-Wen Zhang,
  • Qiong Yuan,
  • Xue-Mei Xu

摘要

In recent years, the utilization of single-port robotic-assisted pyeloplasty (SP-RP) has been growing. However, it is still unclear whether it offers better outcomes relative to multi-port robotic-assisted pyeloplasty (MP-RP). To investigate this, a meta-analysis was executed comparing the perioperative and functional outcomes between SP-RP and MP-RP. We systematically searched SinoMed, Google Scholar, Embase, PubMed, and Scopus, up to June 1, 2025. All outcomes were pooled using a random-effects model, heterogeneity was assessed using both I2 and τ2. Additionally, sensitivity analyses were executed to stabilize results with high heterogeneity. This meta-analysis included 229 patients from seven studies, who underwent either SP-RP or MP-RP. Regarding surgical success rates, patients undergoing SP-RP or MP-RP demonstrated comparable effectiveness (RR = 1.00, 95% CI 0.96 to 1.06, P = 0.87, I2 = 0%, τ2 = 0). Compared to patients receiving MP-RP, patients undergoing SP-RP showed similar results in surgery time (WMD = −2.81 min, 95% CI −20.94 to 15.32 min, P = 0.76, I2 = 72%, τ2 = 409.36), blood loss(WMD =  −3.97 ml, 95% CI −9.25 to 1.30 ml, P = 0.14, I2 = 32%, τ2 = 12.61), complication rates(RR = 0.90, 95% CI 0.42 to 1.92, P = 0.78, I2 = 0%, τ2 = 0), length of hospital stay (WMD = −0.42 days, 95% CI −0.90 to 0.06 days, P = 0.09, I2 = 74%, τ2 = 0.25), pain scores at discharge (WMD = 0.23, 95% CI −0.52 to 0.97, P = 0.55, I2 = 37%, τ2 = 0.17), and renal function recovery(WMD = 0.79 mL/min/1.73 m2, 95% CI −4.59 to 6.17 mL/min/1.73 m2, P = 0.77, I2 = 67%, τ2 = 10.88). Statistically, the differences between the two were not significant. However, during the sensitivity analysis, compared to MP-RP, we found that excluding Beksac’s study led to a significantly shorter hospital stay for SP-RP. This exclusion also reduced heterogeneity, resulting in more stable outcomes (WMD = −0.31 days, 95% CI −0.56 to −0.06 days, P = 0.01, I2 = 0%, τ2 = 0). SP-RP offers comparable effectiveness and safety to MP-RP, with consistently better cosmetic outcomes. A possible reduction in hospital stay was observed only in the sensitivity analysis and should be interpreted with caution.